

Page 3  
Serial No. 09/600,060  
Response to Official Action

**DRAFT**

**In the Claims**

1-100. (Cancelled)

101. (New) A method for treating a subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives comprising administering to the subject an effective amount of an agent wherein the agent is selected from the group consisting of Etx, Ctx, EtxB, and CtxB that bind to GM1 wherein the agent is administered with an allergen and is not coupled to said allergen.

102. (New) The method according to claim 101 wherein the method is a method of treating said subject for asthma.

103. (New) The method according to claim 101 wherein the method is a method of treating said subject for allergic rhinitis.

104. (New) The method according to claim 101 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously

105. (New) A method for treating a subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives comprising administering to the subject an effective amount of EtxB that binds to GM1 wherein the EtxB is administered with an allergen and is not coupled to said allergen.

106. (New) The method according to claim 105 wherein the method is a method of treating said subject for asthma.

107. (New) The method according to claim 105 wherein the method is a method of treating said subject for allergic rhinitis.

Page 4  
Serial No. 09/600,060  
Response to Official Action

**DRAFT**

108. (New) The method according to claim 105 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously
109. (New) A method for treating a subject for asthma comprising administering to the subject an effective amount of an agent wherein the agent is EtxB that binds to GM1.
110. (New) The method according to claim 109 wherein the agent is administered mucosally.
111. (New) A method for treating a subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives comprising administering to the subject an effective amount of an agent wherein the agent is EtxB that binds to GM1.
112. (New) The method according to claim 111 wherein the method is a method of treating said subject for asthma.
113. (New) The method according to claim 111 wherein the method is a method of treating said subject for allergic rhinitis.
114. (New) The method according to claim 111 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously